Regeneron stock trades lower as insider sales and lawsuit weigh on sentiment

Regeneron stock is trading below recent highs as new insider selling disclosures and a fresh securities class action highlight ongoing fallout from a failed melanoma trial, while analysts still see upside based on strong recent earnings.

Regeneron Pharmaceuticals stock (ISIN US75886F1075) is changing hands around 843.47 USD as of September 4, 2026, down about 1.0% from the prior close and noticeably below levels above 850 USD seen earlier this week according to recent market data compiled by MarketBeat.

Insider sales add pressure after prior price drop

A fresh catalyst for the Regeneron stock narrative comes from newly reported insider transactions filed with the U.S. Securities and Exchange Commission on September 3, 2026. According to a Form 4 summary compiled by StockTitan, Regeneron executive vice president Marion McCourt sold 1,131 shares of company stock at 857.39 USD per share on September 3, 2026, following a sale of 1,215 shares at 850.00 USD per share on September 2, 2026.

In a separate filing summarized by StockTitan, a Regeneron director exercised options for 400 shares at an exercise price of 719.37 USD per share and sold the same 400 shares at 850.00 USD per share on September 2, 2026 under a pre-arranged Rule 10b5-1 trading plan. For investors, these insider sales at prices in the 850 to 857 USD range underline how the current 843.47 USD trading level sits slightly below the levels insiders were recently able to realize.

Class action lawsuit follows failed melanoma trial

The backdrop to the current sentiment around Regeneron stock includes a newly highlighted securities class action related to a failed Phase 3 melanoma trial. As reported in an investor alert by Hagens Berman Sobol Shapiro on September 3, 2026, the law firm has filed a securities fraud class action against Regeneron after surprising revelations about the protocol and ultimate failure of a Phase 3 clinical trial for a melanoma therapy.

The alert notes that news of the trial failure previously drove Regeneron shares sharply lower, erasing about 11 billion USD in market capitalization and prompting the lawsuit, which seeks to represent investors who bought Regeneron common stock between August 1, 2025 and May 15, 2026. A separate investor notice summarized by Morningstar states that Regeneron shares fell approximately 13.95%, or 102.09 USD per share, from a closing price of 731.77 USD on April 28, 2026 to 629.68 USD on May 18, 2026 following the alleged corrective disclosures.

Analyst consensus still points to upside

Despite the legal overhang, recent data show that the analyst community remains broadly constructive on Regeneron stock. According to an overview published by MarketBeat on September 4, 2026, the company currently has a consensus rating of Moderate Buy and a consensus price target of 800.36 USD per share based on aggregated analyst estimates.

The same MarketBeat summary notes that Regeneron Pharmaceuticals shares opened at 843.47 USD on the referenced trading day, implying that the consensus price target of 800.36 USD sits modestly below the current market level. The narrow gap between the 843.47 USD opening price and the 800.36 USD analyst target highlights a relatively balanced view: analysts see fundamental support but only limited additional upside from today’s price, especially after the stock’s recovery from the May 2026 low of 629.68 USD cited in the class action notice.

Representative therapy from Regeneron portfolio

Regeneron Pharmaceuticals is best known to many patients and physicians for its injectable biologic treatments, which target immune pathways in conditions ranging from eye disease to inflammatory disorders. A key representative product is the company’s monoclonal antibody therapies used in oncology and immunology, which rely on Regeneron’s proprietary technology platforms to generate and optimize candidate antibodies for clinical development.

Regeneron stock price and investor perspective

Based on recent market snapshots reported by MarketBeat and other stock portals as of September 4, 2026, Regeneron stock is trading around 843.47 USD on the Nasdaq, with intraday moves that have kept it within a range just below the 850 USD levels where insiders recently sold part of their holdings. For investors, the combination of prior sharp declines linked to the failed melanoma trial, current insider sales at slightly higher prices, and a consensus analyst target of 800.36 USD frames Regeneron as a large-cap biotechnology name where legal and pipeline risks now sit alongside solid earnings and a still supportive, but cautious, analyst view.

Regeneron stock facts

• Company: Regeneron Pharmaceuticals Inc.
• ISIN: US75886F1075
• Ticker: REGN
• Trading venue: NASDAQ
• Price (as of September 4, 2026): 843.47 USD
• Market capitalization: tens of billions USD (as of September 4, 2026)
• Sector / Industry: Biotechnology / Pharmaceuticals
• Index membership: S&P 500